CelLBxHealth (AIM:CLBX) announced it has signed a Master Services Agreement with a Swiss biotech company to support a radiopharmaceutical clinical study.
The AIM-listed company specialises in circulating tumour cell (CTC) intelligence through its Parsortix platform, a microfluidic system that captures and harvests intact CTCs from blood samples for use in research, drug development and clinical oncology.
"We are pleased to support the programme," said Dr Jan Groen, Executive Chairman of CelLBxHealth, adding that the company aims "to generate data that may help the Swiss biotech company explore the role of CTCs in its future research and clinical applications."
The deal extends a run of contract wins this year, following a Master Services Agreement with AstraZeneca in May naming CelLBxHealth a qualified service provider for clinical-trial sample analytics, and a statement of work signed earlier this month with a US-based pharmaceutical company to process around 100 patient samples.
CelLBxHealth previously reiterated FY 2026 revenue guidance of at least £2.1 million at its half-year results in July, having reported £0.6 million in first-half revenue and a commercial pipeline of £3.5 million, with cash of £2.9 million at the period end and stated runway into the second quarter of 2027.
Read more about CelLBxHealth